Bladder, kidney, and other urologic cancers:
Indications for: Thiotepa
Superficial papillary carcinoma of the urinary bladder. Intracavitary effusion due to neoplasm of serosal cavities.
Adult Dosage:
Avoid fluids 8–12 hrs prior to treatment. 60mg once weekly for 4 weeks; may repeat up to a total of 3 courses. Retain in bladder for 2 hours. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.
Children Dosage:
Not recommended.
Thiotepa Contraindications:
Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.
Thiotepa Warnings/Precautions:
Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Thiotepa Classification:
Alkylating agent.
Thiotepa Interactions:
Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.
Adverse Reactions:
Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.
Note:
Formerly known under the brand name Thioplex.
How Supplied:
Contact supplier.
Breast cancer:
Indications for: Thiotepa
Adenocarcinomas of the breast. Intracavitary effusion due to neoplasm of serosal cavities.
Adult Dosage:
0.3–0.4mg/kg IV once every 1–4 weeks. Intracavitary administration: 0.6–0.8mg/kg through same tube used to remove fluid from cavity.
Children Dosage:
Not recommended.
Thiotepa Contraindications:
Renal, hepatic, or bone marrow dysfunction; if need outweighs risk, may be used in low dosage with close monitoring.
Thiotepa Warnings/Precautions:
Bone marrow suppression; monitor blood and platelets weekly during and for at least 3 weeks after therapy. Discontinue if WBC ≤3000/mm3 or platelets ≤150,000/mm3. Monitor renal and hepatic function. Use effective contraception if patient or partner is of childbearing potential. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Thiotepa Classification:
Alkylating agent.
Thiotepa Interactions:
Increased toxicity with concomitant or sequential alkylating agents (nitrogen mustards, cyclophosphamide), radiation, myelosuppressants. Prolonged apnea with succinylcholine.
Adverse Reactions:
Myelosuppression, fatigue, febrile or allergic reactions, inj site reactions, urinary retention, dysuria, GI disturbances, anorexia, alopecia, dizziness, headache, drowsiness, blurred vision, amenorrhea, interferes with spermatogenesis. Intravesical administration: rare: chemical or hemorrhagic cystitis.
Note:
Formerly known under the brand name Thioplex.
How Supplied:
Contact supplier.
